

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | | | |
|---|--|----------------|----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Alkermes Pharma Ireland Limited | FORMERLY ELAN PHARMA INTERNATIONAL LIMITED PRIVATE LIMITED COMPANY | 10/31/2013 | CORPORATION: IRELAND |
| RECEIVING PARTY DATA | | | |
| Name: | Alvogen Pharma US Inc. | | |
| Street Address: | 10 Bloomfield Ave, Building B | | |
| City: | Pine Brook | | |
| State/Country: | NEW JERSEY | | |
| Postal Code: | 07058 | | |
| Entity Type: | CORPORATION: NEW JERSEY | | |
| PROPERTY NUMBERS Total: 2 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 73659443 | NAPRELAN | |
| Registration Number: | 1955461 | NAPRELAN | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 9737963439 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 9734873948 | | |
| Email: | andrea.sweet@alvogen.com | | |
| Correspondent Name: | Andrea Sweet | | |
| Address Line 1: | 10 Bloomfield Ave, Building B | | |
| Address Line 2: | Alvogen Pharma US Inc | | |
| Address Line 4: | Pine Brook, NEW JERSEY 07058 | | |
| NAME OF SUBMITTER: | Andrea Sweet | | |
| Signature: | /Andrea Sweet/ | | |

OP \$65.00 73659443

Date:

11/04/2013

Total Attachments: 4

source=Naprelan TM DEED B&W#page1.tif

source=Naprelan TM DEED B&W#page2.tif

source=Naprelan TM DEED B&W#page3.tif

source=Naprelan TM DEED B&W#page4.tif

CONFIDENTIAL

DEED OF ASSIGNMENT

Between

ALKERMES PHARMA IRELAND LIMITED

and

ALVOGEN PHARMA US, INC.

NAPRELAN – U.S. Trademark

CONFIDENTIAL

THIS DEED OF ASSIGNMENT is made October 31, 2013

BETWEEN:

- (1) Alkermes Pharma Ireland Limited, a private limited company incorporated under the laws of Ireland, with its registered office at Connaught House, 1 Burlington Road, Dublin 4, Ireland ("Assignor");
 - (2) Alvogen Pharma US, Inc., a corporation organized and existing under the laws of the State of Delaware, with an office at 10 Bloomfield Ave, Bldg B, Pine Brook, NJ 07058, U.S.A. ("Assignee")
- (Assignor and Assignee hereinafter each individually referred to as a "Party", and collectively referred to as "the Parties")

WHEREAS:

- A. Pursuant to the Naprelan® Asset Assignment Agreement of even date herewith between the Assignor, the Assignee and Shionogi, Inc., the Assignor agreed to assign trade mark registration number 1955461 for the trade mark NAPRELAN for the United States and the associated goodwill (the "Trade Mark") to the Assignee.
- B. The Assignor, as the legal and beneficial owner of the Trade Mark now wishes to transfer the Trade Mark, and its rights, duties, obligations and liabilities under or related to the Trade Mark (the "Trade Mark Rights") to the Assignee under the terms and conditions set out below.

THE PARTIES AGREE as follows:

1. ASSIGNMENT:

In consideration of the payment of U.S. \$1 (one U.S. dollar), receipt of which is hereby acknowledged, and subject always to the Closing of the Asset Sale on or by 30 October 2013 (as those terms are defined in the Naprelan® Asset Assignment Agreement), the Assignor hereby assigns and transfers to the Assignee all right, title and interest in and to the Trade Mark Rights as of the date of the last Party to sign below, and the Assignee accepts such assignment and transfers.

2. GOVERNING LAW AND JURISDICTION:


This Deed of Assignment shall be governed by and construed in accordance with the laws of Ireland, without regard to the conflicts of laws provisions thereof and the parties hereby submit to the exclusive jurisdiction of the Irish courts in the event of any dispute arising out of, in connection with, or in any way related to this Deed of Assignment or its formation.

CONFIDENTIAL

EXECUTED by the Parties as a deed and delivered on the date of the last Party to sign below

Executed as a Deed by:

ALVOGEN GROUP, INC.


By: 

Name: Kevin Bain

Title: Chief Financial Officer

Date: October 31, 2013



By: 

Name: Lisa Graver

Title: Executive Vice President, Strategic Operations

Date: October 31, 2013

ALKERMES PHARMA IRELAND LIMITED

By: Richard Paul

Name: RICHIE PAUL

Title: DIRECTOR

Date: OCTOBER 31 2013

By: SARAH LOCKE

Name: SARAH LOCKE

Title: PRESIDENT

Date: OCTOBER 31 2013

